WO2005094870A3 - Agent de formation de reseau vasculaire - Google Patents
Agent de formation de reseau vasculaire Download PDFInfo
- Publication number
- WO2005094870A3 WO2005094870A3 PCT/IB2005/051141 IB2005051141W WO2005094870A3 WO 2005094870 A3 WO2005094870 A3 WO 2005094870A3 IB 2005051141 W IB2005051141 W IB 2005051141W WO 2005094870 A3 WO2005094870 A3 WO 2005094870A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- variant
- glycine
- svvglr
- treatment
- isoleucine
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004264 Osteopontin Human genes 0.000 title 1
- 108010081689 Osteopontin Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 208000023589 ischemic disease Diseases 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 7
- 239000004471 Glycine Substances 0.000 abstract 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 3
- 235000004279 alanine Nutrition 0.000 abstract 3
- 229960000310 isoleucine Drugs 0.000 abstract 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 3
- 239000004474 valine Substances 0.000 abstract 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne un procédé permettant d'obtenir une substance capable de former un réseau vasculaire. Cette invention concerne également un nouvel agent de formation de réseau vasculaire comprenant une telle substance en tant que principe actif, lequel agent peut être utilisé dans des applications cliniques, telles que pour des êtres humains, entre autres. L'invention concerne également une composition permettant de former un réseau de vaisseaux sanguins, laquelle comprend un peptide présentant une séquence d'acides aminés X1-X2-X3-X4-X5-X6-X7 (SEQ ID NO.: 14), X1 représente la sérine (S), la thréonine (T), ou une variante de celles-ci, ou il est absent, X2 représente la valine (V), l'alanine (A), la glycine (G), la leucine (L), l'isoleucine (I), ou une variante de celles-ci, X3 représente la valine (V), l'alanine (A), la glycine (G), la leucine (L), l'isoleucine (I), ou une variante de celles-ci, X4 représente un acide aminé présentant un noyau aromatique et comprenant une chaîne latérale ou une variante de celui-ci, X5 représente la glycine (G) ou une variante de celle-ci, X6 représente la leucine (L), l'alanine (A), la glycine (G), la valine (V), l'isoleucine (I), ou une variante de celles-ci, X7 représente l'arginine (R ), la lysine (K), ou une variante de celles-ci, ou il est absent; ou une variante ou un sel de cette séquence.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPPCT/JP2004/004747 | 2004-03-31 | ||
| PCT/JP2004/004747 WO2005099742A1 (fr) | 2004-03-31 | 2004-03-31 | Agent de formation de reseau vasculaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005094870A2 WO2005094870A2 (fr) | 2005-10-13 |
| WO2005094870A3 true WO2005094870A3 (fr) | 2006-03-16 |
Family
ID=34957645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/004747 WO2005099742A1 (fr) | 2004-03-31 | 2004-03-31 | Agent de formation de reseau vasculaire |
| PCT/IB2005/051141 WO2005094870A2 (fr) | 2004-03-31 | 2005-03-30 | Agent de formation de reseau vasculaire |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/004747 WO2005099742A1 (fr) | 2004-03-31 | 2004-03-31 | Agent de formation de reseau vasculaire |
Country Status (1)
| Country | Link |
|---|---|
| WO (2) | WO2005099742A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009086106A1 (fr) * | 2007-12-21 | 2009-07-09 | Mount Sinai School Of Medicine Of New York University | Utilisation de protéine de podocan dans le traitement de maladies cardiovasculaires |
| US20150190460A1 (en) * | 2012-07-20 | 2015-07-09 | Forsyth Dental Infirmary For Children (D/B/A The Forsyth Institute) | Osteopontin peptide fragments for use in suppression or prevention of tumor growth |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001071358A1 (fr) * | 2000-03-23 | 2001-09-27 | Glaxo Group Limited | Procede de recherche par criblage d'inhibiteurs de l'osteopontine |
| WO2003030925A1 (fr) * | 2001-10-02 | 2003-04-17 | Kiyoshi Nokihara | Medicaments d'angiogenese |
| WO2004050133A2 (fr) * | 2002-12-05 | 2004-06-17 | Cardio Incorporated | Implant biocompatible et son utilisation |
-
2004
- 2004-03-31 WO PCT/JP2004/004747 patent/WO2005099742A1/fr active Application Filing
-
2005
- 2005-03-30 WO PCT/IB2005/051141 patent/WO2005094870A2/fr not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001071358A1 (fr) * | 2000-03-23 | 2001-09-27 | Glaxo Group Limited | Procede de recherche par criblage d'inhibiteurs de l'osteopontine |
| WO2003030925A1 (fr) * | 2001-10-02 | 2003-04-17 | Kiyoshi Nokihara | Medicaments d'angiogenese |
| EP1452182A1 (fr) * | 2001-10-02 | 2004-09-01 | Kiyoshi Nokihara | Medicaments d'angiogenese |
| WO2004050133A2 (fr) * | 2002-12-05 | 2004-06-17 | Cardio Incorporated | Implant biocompatible et son utilisation |
Non-Patent Citations (3)
| Title |
|---|
| HAMADA, Y. ET AL.: "Angiogenic activity of osteopontin-derived peptide SVVYGLR", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 310, no. 1, 10 October 2003 (2003-10-10), pages 153 - 157, XP004457198 * |
| HAMADA, Y. ET AL.: "Osteopontin-derived Peptide SVVYGLR Induces Angiogenesis In Vivo", DENTAL MATERIALS JOURNAL, vol. 23, no. 4, December 2004 (2004-12-01), pages 650 - 655, XP008052345 * |
| NOKIHARA. K. ET AL.: "Development of a simple and low cost manual synthesizer for chemical library construction", PEPTIDE SCIENCE, vol. 38, 2002, pages 61 - 64, XP009040162 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005094870A2 (fr) | 2005-10-13 |
| WO2005099742A1 (fr) | 2005-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101111256B (zh) | 抗菌肽及其使用方法 | |
| JP5688290B2 (ja) | 抗菌性ペプチド | |
| Tam et al. | Thia zip reaction for synthesis of large cyclic peptides: Mechanisms and applications | |
| US9352015B2 (en) | Antimicrobial peptides | |
| ATE477020T1 (de) | Prevention und verringerung von ischemia | |
| CA2489227A1 (fr) | Peptides d'antigene du cancer a restriction hla-a24 | |
| NO333073B1 (no) | Cytotoksiske peptider modifisert med en eller flere ikke-genetiske, voluminose og/eller lipofile aminosyrer. | |
| JP2019533722A5 (fr) | ||
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| WO2020060401A2 (fr) | Peptides bioactifs issus de serpents | |
| WO2010042534A1 (fr) | Peptides et procédés d'utilisation | |
| MXPA06014393A (es) | Peptidos oligomericos y su uso para el tratamiento de infecciones por vih. | |
| DE60231649D1 (de) | Mittel zur behandlung von augentrockenheit und damit zusammenhängenden erkrankungen | |
| WO2005094870A3 (fr) | Agent de formation de reseau vasculaire | |
| NZ591827A (en) | Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject | |
| US20200071357A1 (en) | Antimicrobial peptides | |
| ATE411812T1 (de) | Peptide zur behandlung von infektionen mit dem herpes-virus | |
| ATE519782T1 (de) | Peptide und ihre verwendung zur behandlung von hiv infektionen | |
| CA2530731A1 (fr) | Peptide presentant une activite d'inhibition de l'apoptose | |
| WO2002100890A3 (fr) | Virus syncytial respiratoire | |
| WO2004011638A3 (fr) | Polypeptides et structures de deoxyuridine 5' triphosphate nucleotidohydrolase | |
| CN102329375A (zh) | 一组末端酰胺化的抗菌肽 | |
| WO2004013167A3 (fr) | Nouveaux polypeptides purifies issus d'enterococcus faecalis | |
| Critical Care Society of South Africa Working Group | Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated) | |
| WO2004058811A3 (fr) | Structures cristallines des polypeptides yhhf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |